Related Experiment Videos
[Economic evaluation of eptifibatide]
1Departamento de Economía y Empresa, Universidad de La Rioja y Soikos, La Cigüeña, 60, 26004 Logroño, Spain. antonanzas@dee.unirioja.es
Revista Espanola De Cardiologia
|February 22, 2001
Summary
The economic evaluation of eptifibatide for unstable angina found the cost per year of life saved is acceptable. This drug offers a modest survival benefit, making its use a viable healthcare investment.
Area of Science:
- Pharmacoeconomics
- Cardiovascular Medicine
- Health Technology Assessment
Background:
- Unstable angina and non-Q wave myocardial infarction require effective treatment strategies.
- The PURSUIT trial evaluated eptifibatide versus placebo in these conditions.
- Economic evaluations are crucial for assessing new medical technologies.
Purpose of the Study:
- To conduct an economic evaluation of the PURSUIT trial in Spain.
- To determine the cost per year of life saved with eptifibatide treatment.
- To assess the cost-effectiveness of eptifibatide for unstable angina.
Main Methods:
- Resource consumption data from the PURSUIT trial were analyzed.
- Unit costs were calculated using an upward cost-aggregation approach.
- Cost-effectiveness was determined by comparing total costs and years of life saved.
Main Results:
- The 6-month cost per patient was comparable between eptifibatide and placebo groups.
- Eptifibatide demonstrated a small survival benefit, saving 2.9 years of life per 100 patients.
- The incremental cost per year of life saved ranged from 1.3 to 3.3 million pesetas.
Conclusions:
- The cost per year of life saved with eptifibatide falls within acceptable limits for new health technologies.
- Results are contingent on the specific resource consumption data utilized.
- Eptifibatide represents a potentially cost-effective treatment option for unstable angina.